[go: up one dir, main page]

AR045875A1 - Procedimiento para la preparacion del antagonista ccr-2 - Google Patents

Procedimiento para la preparacion del antagonista ccr-2

Info

Publication number
AR045875A1
AR045875A1 ARP040103770A ARP040103770A AR045875A1 AR 045875 A1 AR045875 A1 AR 045875A1 AR P040103770 A ARP040103770 A AR P040103770A AR P040103770 A ARP040103770 A AR P040103770A AR 045875 A1 AR045875 A1 AR 045875A1
Authority
AR
Argentina
Prior art keywords
preparation
methoxytetrahydro
pyran
trifluoromethyl
naphthyridine
Prior art date
Application number
ARP040103770A
Other languages
English (en)
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of AR045875A1 publication Critical patent/AR045875A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/24—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/36—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of amides of sulfonic acids
    • C07C303/40—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of amides of sulfonic acids by reactions not involving the formation of sulfonamide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/325—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • C07D207/327—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/10—Systems containing only non-condensed rings with a five-membered ring the ring being unsaturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente proporciona una síntesis para la preparación de ((1R,3S)-3-isopropil-3-{[3-(trifluorometil)-7,8-dihidro-1,6-naftiridin-6(5H)-il]carbonil}ciclopentil)[(3S,4S)-3-metoxitetrahidro-2H-piran-4-il]amina y su sal succinato. La presente proporciona adicionalmente una síntesis para la preparación de los intermedios (3R)-3-metoxitetrahidro-4H-piran-4-ona; ácido (1S,4S)-4-(2,5-dimetil-1H-pirrol-1-il)-1-isopropilciclopent-2-eno-1-carboxílico; y 3-(trifluorometil)-5,6,7,8-tetrahidro-1,6- naftiridina; y para la preparación del precursor (3S,4S)-N-((1S,4S)-4-isopropil-4-{[3-(trifluorometil)-7,8-dihidro-1,6-naftiridin-6(5H)-il]carbonil}ciclopent-2-en-1-il)-3-metoxitetrahidro-2H-piran-4-amina. Adicionalmente reside en las propiedades superiores de la sal succinato de ((1R,3S)-3-isopropil-3-{[3-(trifluorometil)-7,8-dihidro-1,6-naftiridin-6(5H)-il]carbonil}ciclopentil)[(3S,4S)-3-metoxitetrahidro-2H-piran-4-il]amina.
ARP040103770A 2003-10-27 2004-10-18 Procedimiento para la preparacion del antagonista ccr-2 AR045875A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US51475403P 2003-10-27 2003-10-27

Publications (1)

Publication Number Publication Date
AR045875A1 true AR045875A1 (es) 2005-11-16

Family

ID=34572776

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040103770A AR045875A1 (es) 2003-10-27 2004-10-18 Procedimiento para la preparacion del antagonista ccr-2

Country Status (11)

Country Link
US (1) US7361765B2 (es)
EP (1) EP1682500A1 (es)
JP (1) JP4551405B2 (es)
CN (1) CN101160286B (es)
AR (1) AR045875A1 (es)
AU (1) AU2004287810B2 (es)
BR (1) BRPI0415862A (es)
CA (1) CA2543250C (es)
IS (1) IS8416A (es)
TW (1) TWI294426B (es)
WO (1) WO2005044795A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4828829B2 (ja) 2002-11-27 2011-11-30 インサイト・コーポレイション ケモカイン受容体のモジュレーターとしての３−アミノピロリジン誘導体
CA2519297A1 (en) * 2003-03-18 2004-09-30 Merck & Co., Inc. Tetrahydropyranyl cyclopentyl heterocyclic amide modulators of chemokine receptor activity
CA2543201C (en) * 2003-10-27 2010-12-21 Merck & Co., Inc. ((ir, 3s)-3-isopropyl-3-{ [3-(trifluoromethyl)-7, 8-dihydro-1, 6-naphthyridin-6 (5h)-yl] carbonyl} cyclopentyl) [(3s, 4s)-3-methoxytetrahydro-2h-pyran-4-yl] amine succinate salt, composition thereof, and its use in the treatment of inflammatory diseases
AP2439A (en) 2003-12-18 2012-08-31 Incyte Corp 3-Cycloalkylaminopyrrolidine derivatives as modulators of chemokine receptors
CN1950085A (zh) 2004-05-11 2007-04-18 因赛特公司 作为趋化因子受体调节剂的3－(4－杂芳基环己基氨基)环戊烷羧酰胺
US20130345254A1 (en) * 2011-03-17 2013-12-26 Anilkumar G. Nair Cyclohexane substituted amino cyclopentane derivatives as useful ccr2 antagonists
US8822460B2 (en) * 2012-04-06 2014-09-02 Janssen Pharmaceutica Nv Fused cyclopentyl antagonists of CCR2
CN104418769A (zh) * 2013-09-03 2015-03-18 苏州安尼康药物研发有限公司 一种化合物及其制备方法
WO2016175068A1 (ja) 2015-04-27 2016-11-03 コニカミノルタ株式会社 有機エレクトロルミネッセンス素子用材料、有機エレクトロルミネッセンス素子、表示装置及び照明装置
RU2726206C2 (ru) 2015-05-21 2020-07-09 Кемосентрикс, Инк. Модуляторы ccr2
CN105968055B (zh) * 2016-07-26 2018-08-28 中国科学院长春应用化学研究所 一种芳基嘧啶及其衍生物的制备方法
US11304952B2 (en) 2017-09-25 2022-04-19 Chemocentryx, Inc. Combination therapy using a chemokine receptor 2 (CCR2) antagonist and a PD-1/PD-L1 inhibitor
MA50423A (fr) 2018-01-08 2020-08-26 Chemocentryx Inc Procédés de traitement de tumeurs solides au moyen d'antagonistes du ccr2
US20190269664A1 (en) 2018-01-08 2019-09-05 Chemocentryx, Inc. Methods of treating solid tumors with ccr2 antagonists

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09291034A (ja) * 1996-02-27 1997-11-11 Yoshitomi Pharmaceut Ind Ltd 縮合ピリジン化合物およびその医薬としての用途
AU2001283345B2 (en) * 2000-08-17 2005-03-24 Merck Sharp & Dohme Corp. Cyclopentyl modulators of chemokine receptor activity
PL367200A1 (en) * 2001-05-15 2005-02-21 E.I.Du Pont De Nemours And Company Pyridinyl fused bicyclic amide as fungicides
SI1501507T1 (sl) * 2002-04-29 2008-12-31 Merck & Co Inc Tetrahidropiranil ciklopentil tetrahidropiridopiridin modulatorji s kemokinsko receptorsko aktivnostjo
CA2543201C (en) * 2003-10-27 2010-12-21 Merck & Co., Inc. ((ir, 3s)-3-isopropyl-3-{ [3-(trifluoromethyl)-7, 8-dihydro-1, 6-naphthyridin-6 (5h)-yl] carbonyl} cyclopentyl) [(3s, 4s)-3-methoxytetrahydro-2h-pyran-4-yl] amine succinate salt, composition thereof, and its use in the treatment of inflammatory diseases

Also Published As

Publication number Publication date
AU2004287810B2 (en) 2011-01-06
CA2543250C (en) 2011-03-29
JP4551405B2 (ja) 2010-09-29
WO2005044795A8 (en) 2006-06-22
CN101160286B (zh) 2012-07-04
TWI294426B (en) 2008-03-11
CN101160286A (zh) 2008-04-09
TW200530233A (en) 2005-09-16
WO2005044795A1 (en) 2005-05-19
JP2007509944A (ja) 2007-04-19
EP1682500A1 (en) 2006-07-26
IS8416A (is) 2006-04-12
US7361765B2 (en) 2008-04-22
US20070135475A1 (en) 2007-06-14
AU2004287810A1 (en) 2005-05-19
CA2543250A1 (en) 2005-05-19
BRPI0415862A (pt) 2007-01-09

Similar Documents

Publication Publication Date Title
IS8400A (is) CCR-2 mótlyfssalt
AR045875A1 (es) Procedimiento para la preparacion del antagonista ccr-2
GEP20125405B (en) Amino-heterocyclic compounds
PA8637601A1 (es) Compuestos moduladores de la actividad de c-kit y usos de los mismos
DK1812440T3 (da) Pyrazolo[1,5-a]pyrimidiner, der kan anvendes som inhibistorer af proteinkinaser
PE20141557A1 (es) Derivado de pirazoloquinolina
WO2009094668A8 (en) New 2,3,4,5-tetrahydro-1h-pyrido[ 4,3-b] indole compounds and methods of use thereof
EP3287449A3 (en) Salts of 2-fluoro-n-methyl-4-[7-(quinolin-6-yl-methyl)- imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same
EP2698160A3 (en) Organic compounds
AR086656A1 (es) Combinacion de inhibidores de mek e inhibidores selectivos de la quinasa aurora a
NO20054208L (no) Nitrogen-substituerte heksahydropyrazino[1,2-a]pyrimidin-4,7-dionderivater, fremgangsmater for fremstilling og anvendelse derav som medikamenter
PH12013501221A1 (en) SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1,2-a]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS
RU2015148189A (ru) ПРОИЗВОДНЫЕ 2-АМИДОПИРИДО[4, 3-d]ПИРИМИДИН-5-ОНА И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ WEE-1
SG195085A1 (en) Pyrazolo[3,4-d]pyrimidine compounds and their use as pde2 inhibitors and/or cyp3a4 inhibitors
IS2095B (is) Salt af naftýridín karboxýlsýru afleiðu
ATE486602T1 (de) Pyrrolo (3, 2, 1-ij) chinolin-4-on-derivate zur behandlung von tuberkulose
ATE348101T1 (de) Carbolin derivate als hemmstoffe von phospphodiesterase 5 (pde5) zur behandlung kardiovaskulärer erkrankungen und der erektilen dysfunktion
CY1109366T1 (el) Υποκατεστημενες ενωσεις 1,4,8-τριαζασπειρο[4.5]δεκαν-2-ονης
BRPI0516003A (pt) composto, uso em um composto ou um éster, um sal farmaceuticamente aceitável ou um hidrato do mesmo, formulação farmacêutica, e, método para a triagem in vitro de ligandos de receptor de prostanóide seletivos
WO2009103476A8 (en) Antitumoral agents with a benzophenanthridine structure and formulations containing them
EA200700144A1 (ru) Производные пиридопиримидина, их получение, их применение в терапии
GEP20247606B (en) Process for producing pharmaceutical dosage forms containing task-1 and task-3 channel inhibitors, and the use of same in breathing disorder therapy
PH12023553203A1 (en) Methods of treating b-cell malignancy using bcl-2 inhibitor
CL2019003848A1 (es) Nueva sal de n-(2,6-dietilfenil)-8-({4-[4-(dimetilamino) piperidin-1-il]-2-metoxifenil}amino)-1-metil-4,5-dihidro-1h pirazolo[4,3-h]quinazolina-3-carboxamida, su preparación, y las formulaciones que la contienen
EA200700963A1 (ru) ТЕРАПЕВТИЧЕСКИЕ ПИРАЗОЛО[3,4-b]ПИРИДИНЫ И ИНДАЗОЛЫ

Legal Events

Date Code Title Description
FA Abandonment or withdrawal